Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHK-Cu
Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II)
A synthetic peptide that inhibits neurotransmitter release at the neuromuscular junction, reducing muscle contraction and the appearance of expression lines. Often called 'topical Botox' in marketing, though the mechanism and potency differ significantly. One of the most commercially successful cosmetic peptides.
A naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Levels decline significantly with age. Widely used in both injectable and topical forms for anti-aging.
Mimics the N-terminal end of SNAP-25, a protein essential for SNARE complex formation and neurotransmitter vesicle fusion. By competing with native SNAP-25, it partially inhibits acetylcholine release at the neuromuscular junction, reducing the intensity of muscle contractions that cause expression wrinkles.
Activates wound healing genes, promotes collagen and elastin synthesis, stimulates blood vessel growth, and has anti-inflammatory and antioxidant properties. The copper ion is essential for many enzymatic processes in tissue remodeling.
- Forehead and crow's feet wrinkle reduction
- Expression line softening
- Preventive anti-aging skincare
- Botox-alternative topical treatment
- Periorbital wrinkle treatment
- Skin rejuvenation and anti-aging
- Wound healing
- Hair growth stimulation
- Collagen production
- Reducing inflammation
- Generally well-tolerated topically
- Much weaker effect than injectable Botox
- Skin irritation possible at high concentrations
- Efficacy debated — some studies show modest results
- Not effective via oral or injectable routes
- Generally well-tolerated topically
- Injectable form has less safety data
- Potential copper toxicity at high doses
- Skin irritation possible with topical use
Not regulated as a drug by the FDA. Classified as a cosmetic ingredient. Available over-the-counter in skincare products. No prescription required. The Ordinary and other brands sell 10% Argireline solutions.
GHK-Cu has a notably complex status after the April 15, 2026 FDA announcement. Injectable GHK-Cu is being removed from Category 2 (significant safety risks), while non-injectable GHK-Cu is simultaneously being removed from Category 1 (active evaluation). Both forms are scheduled for a unified PCAC review before February 2027. Topical cosmetic use is unaffected. Injectable use is now in regulatory gray zone — compounding pharmacies should not assume authorization until PCAC acts.
PCAC: By February 2027
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.